vimarsana.com

Latest Breaking News On - Nasdaq vxrt - Page 3 : vimarsana.com

Vaxart Inc (VXRT): Lucky investors are lined up for success

At the end of the latest market close, Vaxart Inc. (VXRT) was valued at $1.82. In that particular session, Stock kicked-off at the price of $1.92 while reaching the peak value of $1.9245 and lowest value recorded on the day was $1.80. The stock current value is $1.88.Recently in News on October 10,

United statesComunidad autonoma de catalunaJames cummingsSean tuckerWorld vaccine congress europeVaxart incChief scientific officerChief medical officerMining ultra rare metalNorth americaEquity ratioRaw stochasticNasdaq vxrtVaxart incAxart inc nasdaq vxrtXrt shares

Vaxart to Present at World Vaccine Congress Europe 2022 on

SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief.

Comunidad autonoma de catalunaJames cummingsMark herrSean tuckerAndrew blazierWorld vaccine congress europeVaxart incChief scientific officerChief medical officerMedia relationsNasdaq vxrt

Vaxart Names Biotech Veteran Ray Stapleton Chief Technology

Dr. Stapleton has more than 20 years of industry experience leading technical, quality and manufacturing operations at commercial and clinical stage.

United statesRay stapletonMark herrAndrew blazierAndrei floroiuIovance biotherapeutics incMary washington college in fredericksburgUniversity of tennesseeVaxart incSynthetic biologics incChief technology officerExecutive vice presidentChief executiveChief operating officerAmerican type culture collectionSynthetic biologics

Vaxart Announces Highly Regarded Biotech Executive Elaine

Dr. Heron brings decades of experience in executive leadership and life sciences research and development to Vaxart's Board.

Julie cherringtonElainej heronMark herrToddc davisAndrew blazierAndrei floroiuPurdue universityLabcyte incAmplyx pharmaceuticals incBiomarin pharmaceutical incAudit committeeLife science incPfizer incBiosystems group of applera corporationTechnology committeePalvella therapeutics inc

Vaxart Provides Business Update and Reports Second Quarter

Top-line data from COVID-19 Phase II study expected in the third quarter of 2022 Vaxart initiates work on vaccine candidates that directly target new.

United statesUnited kingdomMark herrAndrew blazierAndrei floroiuExchange commission onWorld health organizationDrug administrationProduct development for vaccines advisory committeeHvivo servicesVaxart incDuke universityChief executiveWuhans onlyScience translational medicineOpen orphan

vimarsana © 2020. All Rights Reserved.